- Home
- ITRM vs PRME Comparison
ITRM vs PRME Comparison
Compare ITRM & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- PRME
- Stock Information
- Founded
- ITRM 2015
- PRME 2019
- Country
- ITRM Ireland
- PRME United States
- Employees
- ITRM N/A
- PRME N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- ITRM Health Care
- PRME Health Care
- Exchange
- ITRM Nasdaq
- PRME Nasdaq
- Market Cap
- ITRM 40.0M
- PRME 191.7M
- IPO Year
- ITRM 2018
- PRME 2022
- Fundamental
- Price
- ITRM $0.92
- PRME $3.80
- Analyst Decision
- ITRM Strong Buy
- PRME Buy
- Analyst Count
- ITRM 2
- PRME 6
- Target Price
- ITRM $7.00
- PRME $9.38
- AVG Volume (30 Days)
- ITRM 528.7K
- PRME 4.2M
- Earning Date
- ITRM 08-13-2025
- PRME 08-04-2025
- Dividend Yield
- ITRM N/A
- PRME N/A
- EPS Growth
- ITRM N/A
- PRME N/A
- EPS
- ITRM N/A
- PRME N/A
- Revenue
- ITRM N/A
- PRME $3,846,000.00
- Revenue This Year
- ITRM N/A
- PRME $104.12
- Revenue Next Year
- ITRM $270.19
- PRME $196.78
- P/E Ratio
- ITRM N/A
- PRME N/A
- Revenue Growth
- ITRM N/A
- PRME 550.76
- 52 Week Low
- ITRM $0.81
- PRME $1.11
- 52 Week High
- ITRM $3.02
- PRME $6.75
- Technical
- Relative Strength Index (RSI)
- ITRM 38.85
- PRME 85.06
- Support Level
- ITRM $0.93
- PRME $2.28
- Resistance Level
- ITRM $1.03
- PRME $2.78
- Average True Range (ATR)
- ITRM 0.04
- PRME 0.38
- MACD
- ITRM -0.00
- PRME 0.16
- Stochastic Oscillator
- ITRM 2.64
- PRME 85.34
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.